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Sleep is homeostatically regulated suggesting a restorative function. Sleep deprivation is compensated by an increase
in length and intensity of sleep. In this study, suppression of sleep was induced pharmacologically by drugs related to
different arousal systems. All drugs caused non-rapid eye movement (NREM) sleep loss followed by different
compensatory processes. Apomorphine caused a strong suppression of sleep followed by an intense recovery. In the
case of ﬂuoxetine and eserine, recovery of NREM sleep was completed by the end of the light phase due to the
biphasic pattern demonstrated for these drugs ﬁrst in the present experiments. Yohimbine caused a long-lasting
suppression of NREM sleep, indicating that either the noradrenergic system has the utmost strength among the
examined systems, or that restorative functions occurring normally during NREM sleep were not blocked. Arousal
systems are involved in the regulation of various wakefulness-related functions, such as locomotion and food intake.
Therefore, it can be hypothesized that activation of the different systems results in qualitatively different waking
states which might affect subsequent sleep differently. These differences might give some insight into the
homeostatic function of sleep in which the dopaminergic and noradrenergic systems may play a more important
role than previously suggested.
Keywords: delta homeostasis, freely moving rats, homeostatic sleep regulation, pharmacological sleep
deprivation, recovery sleep, sleep rebound
Introduction
Wakefulness (W) is a complex behavioral state in which subjects are highly responsive to
environmental stimuli. In the mammalian brain, multiple W-promoting cell groups have been
identiﬁed forming arousal pathways that provide widespread innervation to the forebrain. The
concept of ascending reticular activating system (ARAS) (53) was the ﬁrst to describe the
arousal-promoting areas in the brainstem. Components of the ARAS were neurochemically
speciﬁed as ﬁbers originating from the noradrenergic (NAergic) locus coeruleus (LC), the
serotonergic (5-HTergic) raphe nuclei (RN), the cholinergic (ACh) pedunculopontine
tegmental (PPT) and laterodorsal tegmental (LDT) nuclei, the histaminergic (His) tuber-
omammillary system, the dopaminergic (DA) substantia nigra pars compacta (SNpc), ventral
tegmental area (VTA), and the ventral periaqueductal gray matter (vPAG). In the forebrain,
further arousing systems have been discovered, among them, the cholinergic cells in the basal
forebrain (BF) reviewed by Brown et al. (15).
Decreased and/or modiﬁed activity of these arousal-promoting systems enables the
appearance of sleep. Its amount and timing is regulated by circadian and homeostatic
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processes. The circadian process facilitates W at those times of the day when activity and
foraging are possible (13). Homeostatic sleep functions are reﬂected by the severe patholog-
ical changes evoked by long-term sleep deprivation (SD) (64). Thus, sleep appears to provide
necessary circumstances for some restorative processes to take place.
Circadian and homeostatic processes are closely linked to each other (13). W generates a
drive for sleep (“sleep pressure” – SP) that is relieved during sleep that occurs when the
environmental circumstances are appropriate (63). Accordingly, SP is high at the beginning
of sleep and decreases during sleep (18). Sleep intensity can be quantiﬁed by the delta wave
activity routinely assessed as EEG delta power below 4 Hz (14).
During SD, SP accumulates. When SD is over, recovery or rebound sleep (RS) is
initiated with increased intensity, reﬂected in the high EEG delta power, and duration (28).
The magnitude of delta power depends on the duration of prior W (23, 75), and may reﬂect
restorative processes in direct connection with sleep function. Therefore, SD provides a mean
to get some insight into the homeostatic role of sleep. SD can be performed by various
instrumental methods (63), while drugs activating some of the arousal systems can also
induce W and/or eliminate delta activity for various durations. In a more conﬁned interpreta-
tion, it is not simply the amount of non-rapid eye movement (NREM) sleep, but the amount
of delta waves that is important for the restorative effect of sleep. This hypothesis provides
the basis of the concept of slow wave or delta homeostasis (25).
If the presence of delta activity during sleep provides the appropriate circumstances for
the restorative processes to occur, then pharmacologically induced loss of sleep and delta
activity should also be followed by RS. However, it is also possible that elimination of sleep
and delta activity by the activation of a given arousal system does not prevent restorative
processes from occurring. In that case, RS will be missing or reduced which might give
important clues on the nature of the restorative processes.
Though the W-promoting effect of drugs affecting different arousal systems have been
intensively researched, the presence or absence of the RS was often overlooked due to the
short recordings. In this study, drugs related to the DAergic, 5-HTergic, NAergic, and
cholinergic systems were used to enhance W and suppress or even deprive sleep. We
deliberately selected widely used and well-known drugs, even if their speciﬁcity is less well
deﬁned. Sleep rebound was followed for 18 h.
Materials and Methods
Surgical procedure
Experiments were performed on six male Sprague-Dawley rats weighing between 310 and
440 g. Electrode implantation was carried out under i.p. ketamine (80 mg/kg)/xylazine
(10 mg/kg) anesthesia. Rats were placed into a stereotaxic frame (David Kopf, Tujunga,
USA), then the skin on the head was opened in the midline and muscles were retracted. To
record EEG activity, 1.1 mm stainless steel screws (Fine Science Tools, North Vancouver,
Canada) were placed into burr holes over the frontal (Br 2.0; L 2.0) and occipital cortices
(Br −4.5; L 2.0) on both sides. An additional screw implanted into the bone over the
cerebellum was used as reference and ground. To monitor electromyographic (EMG) activity,
a pair of 250 μm Teﬂon-insulated stainless steel wires was inserted into the neck musculature.
All leads were soldered to a miniature connector prepared from a standard 50 × 2 connector
strip and the skull was covered with acrylic resin (Cranioplastic cement, Plastic One,
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Roanoke, USA). Recording sessions started after 1–2 weeks of recovery. Experiments were
carried out in accordance with the European Communities Council Directive of November
24, 1986 and with the guidelines of the local Animal Care and Use Committee. All efforts
were made to minimize the number of animals used and their suffering.
Housing
Rats were kept in a LD12:12 cycle (lights on at 09:30 h) and were housed in individual cages
located in a sound-attenuated room throughout the whole experiment. The cages were
prepared from clear Plexiglass cylinders (height: 330 mm, diameter: 300 mm). Water and
standard laboratory chow were available ad libitum.
Rats were connected to the recording apparatus 2 days before the treatments to allow
habituation to the recording situation. Flexible ﬂat cables connected the rats to swivels ﬁxed
above the large Plexiglass cylinders during the recordings. Cables were folded to a zigzag
shape with a rubber string running in the middle to provide free movements of the rat.
EEG recording
EEG was recorded between the frontal and occipital electrode pairs on both sides through
home-designed headstages based on TLC2264I (Texas Instruments, USA) operational
ampliﬁers built into the male connector. Signals from the both sides were recorded, but
the best signal with least artifacts was analyzed.
Signals were ampliﬁed (1,000×), ﬁltered in two steps (0.3 Hz to 1 kHz followed by
0.364 Hz), then digitalized at a 12-bit resolution by an analog-to-digital (A/D) converter card
(UAM-3216) and stored by a custom-made software for further analysis. The A/D sampling
frequency was set to 128 Hz to yield 512 point in 4 s in order to facilitate Fast Fourier
Transformation (FFT) of the signals. EMG was ﬁltered in the same way for technical reasons.
All EEG and EMG data obtained during the recording sessions were stored on hard disk for
ofﬂine analysis.
Treatments
Drug administration was carried out at the beginning of the light phase (LP). After the
injections, recording sessions started immediately and lasted for 18 h. Six rats were recorded
simultaneously. Each rat received all treatments and the vehicle in random order. At least 3
days elapsed between subsequent injections in the same rat.
The effects of four drugs were tested in doses as follows: the non-selective DA receptor
agonist apomorphine (1 mg/kg corresponding to 3.2 μmol/kg), the selective 5-HT reuptake
inhibitor (SSRI) ﬂuoxetine (10 mg/kg corresponding to 25 μmol/kg), the adrenergic alpha-2
inhibitory autoreceptor antagonist yohimbine (2 mg/kg corresponding to 5 μmol/kg), and the
acetylcholinesterase (AChE) inhibitor eserine (0.2 mg/kg corresponding to 0.7 μmol/kg). All
drugs were dissolved in 0.4% methyl cellulose (Methocel F4M, Dow Chemical Company,
USA) as vehicle. Drug doses were selected on the basis of previous literature data (49, 58, 72).
Solutions were freshly prepared before the recording sessions. Drugs were administered
intraperitoneally (i.p.) except for apomorphine that was injected subcutaneously (s.c.)
complying with the instructions of the supplier. Administered volumes were kept between
1.0 and 1.2 ml in the case of i.p. injections, and between 0.14 and 0.18 ml in the case of s.c.
injections depending on the actual weight of the rat. Each rat received all drug treatments and
a separate control (vehicle) injection in a randomized fashion. When all recordings were
completed, the animals were sacriﬁced by an i.p. overdose of urethane.
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Data analysis
Sleep scoring. Sleep stages were scored using custom-made semi-automatic software. Power
spectra were calculated using the FFT algorithm for all consecutive 4-s periods from all
recordings. Power was integrated in the delta (0.5–4.0 Hz), theta (4.0–9.0 Hz), alpha (9.0–
14.0 Hz), and beta (14.0–48.0 Hz) frequency ranges and the ratio of the theta/delta power was
determined. EMG data were also processed using the FFT method and the total power
(variance) was calculated in the 5.0–48.0 Hz range.
Epochs containing movement artifacts (high delta power and high EMG variance) and
rapid eye movement (REM) sleep epochs (low delta power, high theta/delta ratio, and low
muscle tone) were manually removed in all recordings by visual inspection of the EEG and
EMG signals.
There are several scoring methods to distinguish NREM sleep and W, either automatic,
based on the calculation of sophisticated variables from the recorded data (65), or manually,
relying on the decision of an experienced scorer visually inspecting the EEG, EMG, and
power curves (55). In all cases, slow wave (<4 Hz) content of the EEG and the level of EMG
activity are the most important indicators used as delta power changes that are closely and
inversely related with the level of cortical arousal (79).
In the present experiments, delta power and EMG thresholds were set individually for
each rat by visually inspecting the raw EEG and EMG data from control recordings. These
objective thresholds were then used to score recordings obtained after the treatments. Epochs
in which delta power was above and EMG value below these thresholds, respectively, were
marked as NREM sleep, while epochs with lower delta power or higher EMG activity as W.
In most animal experiments, only W, NREM, and REM sleep epochs are distinguished
[i.e., (54, 57)]. In the present experiments, we further divided W into active wakefulness
(AW) and quiet wakefulness (QW), and NREM into light sleep (LS) and deep sleep (DS)
based on the delta power values (77). Our intention by scoring recorded epochs into ﬁve
categories instead of three was to provide a ﬁner frame for analyzing the level of cortical
activation within W and NREM sleep following pharmacologically evoked SD. Scoring of
S–W epochs into four or ﬁve categories has been used by various automated scoring systems
(67, 83) and in several other laboratories (12, 63). Raw hypnograms were smoothed,
i.e., every 32-s period was assigned to the dominant S–W stage (26).
Analysis of rebound sleep. To examine the effect of the applied drugs on sleep and the
following rebound, lengths of S–W stages were analyzed in four overlapping periods starting
immediately after drug administration. Sleep delta power was also calculated in the same four
periods. As drug effects were expected to be the most pronounced in the ﬁrst 2 h, this period
was analyzed separately (“deprivation period,” hours 1–2). As drug administration was
carried out at the beginning of the LP, characterized by a dominance of sleep over W, ceasing
of drug effects led to an immediate rebound in most cases. To assess the success of this early
rebound, the ﬁrst 4 h (hours 1–4) were analyzed together as “initial period.” In most cases, the
ﬁrst, intense rebound was not able to completely compensate for the lost sleep and delta
power. To get a better picture about the long-term recovery process, S–W stages and delta
power were followed to the end of the LP (hours 1–12), and through the ﬁrst 6 h of the dark
phase (DP): “total recording time” (hours 1–18).
Integrated delta power increases during RS either because of more frequent sleep epochs
or because of more intense sleep (higher delta power) within the epochs. To distinguish
between these two possibilities, delta intensity was calculated at a resolution of 1 h (sleep
delta power/total length of sleep epochs in the given hour).
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Statistical analysis. The extent of recovery in S–W stages was statistically tested in the four
periods deﬁned above starting immediately after drug administration. As these periods were
not independent, repeated-measures analysis of variance (ANOVA) was calculated separately
for each period: hours 1–2 (deprivation period), hours 1–4 (initial period), hours 1–12 (LP),
and hours 1–18 (total recording time). ANOVA was followed by post-hoc tests of Dunnett.
Signiﬁcance of delta intensity changes was analyzed by the two-way mixed-design ANOVA
method (split-plot) with time and treatment as factors, followed by post-hoc tests of Student–
Newman–Keuls. All tests were two-tailed and p< 0.05 was accepted as the lowest limit of
signiﬁcant difference. Data are shown as mean ± SEM on ﬁgures. Data were plotted in
Microcal Origin (OriginLab Corporation, Northampton, USA). Final editing was performed
using Adobe Photoshop CS2.
Results
Deprivation period – NREM
Drug injections were performed at the beginning of the LP, when sleep dominates. The
injection procedure caused transient, non-speciﬁc arousal in all rats, even in controls,
increasing W and decreasing NREM sleep.
Following treatment with vehicle only, the amount of delta power peaked in hours 1–2
and in parallel, DS occupied more than half of hour 2 (Fig. 1). During the LP, delta power
decreased continuously with a visible drop around the light–dark transition after which it had
a stable level. DS changed in parallel, falling below 10% of time after the light–dark
transition, and remaining at this level for the rest of the recording. In contrast, the total amount
of LS increased continuously during the LP reaching its peak during the second part of this
period, to decrease to a low level, slightly above 10%, at the light–dark transition and staying
at this level during the DP. It means that the total amount of NREM sleep (LS + DS) was more
or less constant during most of the LP, but there was a shift from high delta power DS to the
more superﬁcial, lower delta power LS level (data not shown).
Injection of drugs enhancing the effect of the arousal systems strongly increased W and
inhibited delta power as well as sleep in the initial period (Fig. 2), as expected. Dividing W
and NREM sleep into two categories based on delta power, i.e., into AW, QW and LS, DS,
respectively, allowed a ﬁner analysis of changes.
Of the drugs tested, apomorphine had the strongest EEG and sleep effects. In the ﬁrst
1.5 h (i.e., during most of the deprivation period), delta power dropped to a very low level that
had no match following any drug treatments in any time period (Fig. 3a). It was also much
lower than the delta power in control recordings during the DP. Accordingly, both DS and LS
decreased (Fig. 2). In ﬁve of the six rats tested, DS was completely suppressed in this period.
Apomorphine caused the largest increment in AW, though QW was almost unchanged
(Fig. 2).
Fluoxetine caused similar, but weaker changes in the EEG and in the distribution of
S–W stages (Figs 2 and 3b) than apomorphine. DS was completely missing in four of the six
rats in the ﬁrst post-injection hour, but LS was unchanged. Fluoxetine increased both AW and
QW.
Yohimbine had a similar inhibiting effect on delta power as ﬂuoxetine (Fig. 3b and c).
DS was suppressed, but LS was unaffected in the ﬁrst two post-injection hours (Fig. 2). Both
AW and QW increased.
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Eserine had the weakest effect on EEG among the four drugs. Delta power was only
inhibited in the ﬁrst hour to rise in the second hour to the same level that was seen in the ﬁrst
hour of control recordings. It gave the impression as if the control curve had been shifted to
the right by 1 h after eserine administration (Fig. 3d). Consequently, there was only a small
decrease in DS, while LS was unchanged, and QW was slightly increased in the deprivation
period (1–2 h, Fig. 2).
Deprivation period – REM
Apomorphine and ﬂuoxetine completely eliminated REM sleep in the ﬁrst hour in all six rats
recorded. Both drugs caused near-complete REM suppression in the second hour as well
(Fig. 2). An even stronger REM suppression was seen following yohimbine treatment: REM
sleep was completely abolished in all six rats in the ﬁrst 2 h (Fig. 2). Eserine abolished REM
sleep in four of the six rats in the ﬁrst hour; however, no changes were seen in the second
hour. Consequently, there was only a slight, non-signiﬁcant decrease in this phase during the
deprivation period.
Recovery – NREM
Following apomorphine, ﬂuoxetine, and yohimbine treatments, signiﬁcant delta power and
sleep loss appeared by the end of the deprivation period (hours 1–2). If sleep occurred, it was
characterized by a low delta power level, thus scored as LS. Therefore, with the exception of
apomorphine, the total length of LS did not change. Rebound started after drug effects
ceased, but by the end of the initial period (hours 1–4), the total sleep time (LS + DS) was still
below and wake time (AW + QW) was above the control value (Fig. 2). However, by the end
Fig. 1. Time course of delta power
(1–4 Hz) values and sleep–wake
stages during the 18-h total
recording period following vehicle
(0.4% methyl cellulose) injections
given at the beginning of the light
phase (n = 6). (a) Changes in the
delta power values at a resolution of
20 min expressed as percent of the
whole-day (18 h) average (100%);
(b) wakefulness; (c) NREM sleep. In
case of (b) and (c), resolution is 1 h.
Distinction of wakefulness into
active (AW) and quiet (QW)
wakefulness and NREM sleep into
light (LS) and deep (DS) sleep
enabled a ﬁner analysis of these
states. Data are expressed as mean ±
SEM
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Fig. 2. Changes in the duration of sleep–wake stages compared to the control (vehicle only) values following
treatments with apomorphine (1 mg/kg, i.e., 3.2 μmol/kg), ﬂuoxetine (10 mg/kg, i.e., 25 μmol/kg), yohimbine
(2 mg/kg, i.e., 5 μmol/kg), and eserine (0.2 mg/kg, i.e., 0.7 μmol/kg) (n = 6). Data were separately analyzed in
overlapping time periods by repeated-measures ANOVA followed by post-hoc tests of Dunnett. Signiﬁcance levels:
*p< 0.05; **p< 0.01. Data are expressed as mean ± SEM
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of the LP, sleep time was completely recovered in the case of apomorphine and ﬂuoxetine
treatment, but not after yohimbine treatment. In contrast to these strong effects, eserine in the
applied dose had short-lasting effects only, and sleep was fully recovered by the end of the
initial period (Fig. 2).
Apomorphine. Delta power and DS were strongly depressed in the ﬁrst three-quarter of the
deprivation period following apomorphine treatment. However, around the middle of hour 2,
there was a sudden, steep increase in delta power peaking above the highest control values.
Delta power exceeded the control level for the whole LP (Fig. 3a). Therefore, DS was
recovered by the end of the initial period (hours 1–4), and it exceeded the control value by the
end of the LP (Fig. 2). In the DP, delta power returned to the control level and the extra DS
gained in the LP did not change any further. The loss in LS was never recovered. LS loss
compensated for the extra DS, thus total NREM (LS + DS) did not differ from the control in
the LP or in the total recording time (Fig. 2).
The very strong rebound of delta power and sleep was caused not only by the increase in
the total time spent in NREM sleep, but also by a strong increase in the delta power intensity
in sleep epochs (Fig. 4a). Delta power intensity (i.e., integrated power in the delta range for a
given unit of NREM sleep time) was elevated practically during the whole recording between
hours 3 and 18, strongly exceeding the level of signiﬁcance between hours 3 and 6.
Fig. 3. Time course of delta power after the different treatments at a resolution of 20 min. (a) Apomorphine,
(b) ﬂuoxetine, (c) yohimbine, and (d) eserine. The black areas indicate delta power after treatments, while the control
values are shown by the gray line. Delta power was normalized by the mean value in the whole control recording
for each rat. The insets in the ﬁgures depict the difference of delta power after drug administration and during the
control recording
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In parallel with the recovery of NREM sleep, W was also restored by the end of the LP,
and only a small, not signiﬁcant excess of AW and loss of QW remained. However, during
the DP, AW was strongly above and QW below the control level, resulting in a signiﬁcant
shift toward the lower delta levels during W for the whole recording time. It was just the
opposite of changes seen in LS and DS (Fig. 2).
Fluoxetine. Following ﬂuoxetine treatment, delta power started to increase toward the end of
the ﬁrst hour, and reached its maximum by hour 3 (Fig. 3b). In contrast to apomorphine,
however, the peak did not exceed the highest control level. In parallel with the increase of
delta power, sleep was also recovered with only a small amount of sleep loss remaining by the
end of the initial period (hours 1–4). NREM recovery was complete by the end of the LP
(Fig. 2). No further changes occurred in the DP.
Delta power intensity decreased during the deprivation period and increased in parallel
with the time spent in DS during recovery. Thus, not only the total sleep time increased, but
more delta power was measured in a given unit time of NREM sleep. However, the
Fig. 4. Delta power intensity following the different treatments. (a) Apomorphine, (b) ﬂuoxetine, (c) yohimbine,
and (d) eserine. To assess whether intensity of sleep as reﬂected in delta power was changed by the treatments,
normalized delta power in NREM sleep (LS + DS) was divided by the total length of these stages at a resolution of
1 h. On all four panels, thick black lines show same control values obtained after vehicle injections. Data are
expressed as mean ± SEM
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enhancement of delta power intensity was much more moderate and lasted for a shorter time
compared to apomorphine treatment (Fig. 4a and b).
In contrast to sleep, extra time gained in AW during the initial period was not
compensated in the LP, though the total length of QW by the end of this period did not
differ from the control (Fig. 2). Then during the DP, a considerable shift was seen toward the
lower delta power values during wakefulness resulting in more AW and less QW, while
NREM did not change (Fig. 2). This pattern was similar to that seen after apomorphine
treatment.
Yohimbine.Yohimbine caused a long-lasting suppression of delta power that was also seen in
the DP (Fig. 3c). Therefore, no real rebound occurred, though the time spent in LS increased
compared to the control in hours 3–4 causing signiﬁcantly higher total LS by the end of the
initial period (1–4 h, Fig. 2). By the end of the recording, a total DS loss of more than 2 h was
seen, while LS did not differ from the control, attesting a strong shift toward the lower delta
power values during sleep (Fig. 3c).
Delta power decreased not only because less time was spent in NREM sleep, but also
because delta power intensity during NREM sleep was also depressed for the whole LP,
though it was only signiﬁcant in the initial period (Fig. 4c).
Corresponding changes were observed in wakefulness. The extra time gained in both
AW and QW during the deprivation period (hours 1–2) was slightly augmented further by the
end of the LP. Then, in the DP, a strong AW dominance over QW appeared, i.e., a strong shift
toward the lower delta power values. QW dropped back to the control level, while AW
sharply increased (Fig. 2).
Eserine. The mildest effect was caused by the eserine treatment. It seemed as if the delta
power curve had been shifted to the right by 1 h (Fig. 3d). Recovery of sleep and wakefulness
was complete by the end of the initial period (hours 1–4); none of the S–W stages differed
signiﬁcantly from the control by the end of this period (Fig. 2). Interestingly, during the DP, a
shift toward the lower delta power values during wakefulness (more AW and less QW)
occurred, similar to the aftereffects of apomorphine and ﬂuoxetine treatments (Fig. 2), but it
only reached the level of signiﬁcance for QW. No further changes were seen in NREM; the
slight, non-signiﬁcant excess of DS over LS gained by the end of the LP remained.
Similarly to the S–W stages, delta power intensity differed only slightly from the control
(Fig. 4d). The only signiﬁcant difference was detected in hour 3. The shape of the curve
strengthened the impression that the drug only shifted the phase of the S–W cycle by 1 h to
the right, and did not have too much other effect.
Recovery – REM
All drugs suppressed REM sleep in the deprivation period (hours 1–2) and during the total
initial period (hours 1–4), though to a different extent (Fig. 2).
Apomorphine caused considerable loss in REM sleep by the end of the initial period
(hours 1–4), but by the end of the LP, recovery was complete (Fig. 2).
Fluoxetine produced the strongest suppression of REM sleep, almost completely
blocking this sleep epoch for 5 h. The loss of REM increased continuously during the LP
reaching about 0.5 h by the end of the period (Fig. 2). Some recovery was seen during the DP,
but at the end of the recording, the loss was still close to 0.5 h that is about 56% of the control
value.
Yohimbine caused the second strongest REM loss reaching more than 10 min by the
end of the initial period (hours 1–4). The loss was not recovered by the end of the LP,
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it diminished only slightly, though at this point, decrease in the total length of REM sleep did
not reach the level of statistical signiﬁcance. The slow recovery continued in the DP, but at
the end of the recording, the loss was still around 8 min (Fig. 2).
Eserine had only a mild, non-signiﬁcant effect on REM sleep that was fully recovered by
the end of the LP (Fig. 2).
Discussion
Drug-induced wake periods might be qualitatively different depending on the drug
In this study, W was evoked pharmacologically through the activation of one of the four
different arousal systems (DAergic, 5-HTergic, NAergic, and cholinergic) examined. In
addition to inducing cortical activation and W, these systems are involved in the regulation of
various physiological functions that are closely related to W, such as stress, sexual behavior,
locomotion, food intake, and to name a few. Therefore, it can be hypothesized that the
activation of the different arousal systems results in qualitatively different W states.
The function of sleep is not known, but shows homeostatic regulation that suggests it has
a restorative function. SD by gentle handling prevents restoration processes occurring during
sleep, thus during RS, delta power increases reﬂecting increased sleep intensity (14). The
qualitatively different W states induced by pharmacological means might affect restoration
differently, leading to speciﬁc delta power and sleep patterns during recovery. These
differences might give some insight into the homeostatic function of sleep.
Apomorphine. DAergic cell groups are located in the midbrain SNpc in the VTA (90), and in
the vPAG (47). Projections from these regions run mostly to the dorsal and ventral basal
ganglia and to the prefrontal cortex (2). DA acts on ﬁve G protein-coupled receptors
(D1–D5) (8).
The importance of the DAergic system in sleep regulation is controversial. Identiﬁed
DAergic VTA neurons showed slow and tonic ﬁring during W and NREM sleep with loose
coupling to the actual S–W stage, while prominent burst ﬁring, known to be associated with
increased DA release, was observed during REM sleep (21). On the other hand, behaviorally
active W was associated with increased forebrain DA release and drugs that stimulate
DA release (cocaine or amphetamine) enhanced arousal (56). In accordance with that,
Parkinson’s disease is associated with an extensive loss of DAergic cells and increased
sleepiness (1), and selective lesion of vPAG DAergic cells resulted in a marked reduction of
W (47).
Apomorphine binds non-selectively to all DA receptor types (3) and is a full agonist on
D1 and D5 receptors and a partial agonist on D2–D4 receptors (35). In addition, it has a
complex receptor binding proﬁle involving non-DA receptors, acting as an antagonist on
5-HT, α1-adrenergic, and α2-adrenergic receptors (51). Thus, apomorphine binding to
non-DA receptors may also be involved in the observed S–W effects.
In the present experiments, administration of apomorphine resulted in continuous active
W for 1.5 h (Fig. 2), which is in accordance with previous data (44). Apomorphine
concentration in the brain peaks 10 min after administration, declining thereafter with a
half-life of about 10 min (11). This fast elimination can explain the strong and short-lasting
wake-inducing effect. Afterward, delta power and DS were signiﬁcantly increased for the
whole LP leading to an overcompensation of DS and a loss in LS. REM sleep was strongly
inhibited for 3 h, but was fully recovered by the end of LP (Fig. 2).
Sleep loss and recovery after arousal system drugs 281
Physiology International (Acta Physiologica Hungarica) 103, 2016
Among the DA receptors, D1 and D2 subtypes play a pivotal role in the S–W effects of
apomorphine (60). D1 receptor activation excited corticopetal BF neurons and cortical ACh
release increased after apomorphine administration (22). D2 receptors are located both
presynaptically and postsynaptically and are also functioning as autoreceptors (27). Activa-
tion of presynaptic D2 receptors decreased, while postsynaptic D2 receptor activation
increased W (38). Autoreceptor-preferring agonists decreased W (7). Taken together,
activation of D1 receptors and postsynaptic D2 receptors might have played a role in
apomorphine effects in this study.
In a previous study (32), we have shown that during RS following SD, delta power
increased mainly due to the increased occurrence of down or inactive states. These states were
always preceded by an increased activity in the cortical neurons giving the impression that
during sleep, the cells were more sensitive to activation and responded with hyperpolariza-
tion, i.e., with down states. In the present experiments, it was not only the amount of DS that
increased after apomorphine effect ceased, but also the delta intensity during sleep (Fig. 4a).
DA is critically involved in highly aroused and highly motivated states (24). It can be
hypothesized that increased activity in these circuits caused by apomorphine led to higher
susceptibility of neurons toward activation during RS and that this factor led to the increased
delta power and delta intensity that was stronger than what was needed to recover lost sleep.
Fluoxetine. 5-HTergic neurons are located in and close to the midline throughout the
brainstem and are divided into several nuclei. The cells provide a widespread innervation
to practically all areas of the central nervous system (85). The effects of 5-HT are mediated by
seven different receptor types known to date (5-HT1–5-HT7) (37).
5-HT participates in several functions including cognition, affection, food intake (40),
and promotes W and inhibits REM sleep (80). Systemic injection of various selective
agonists of either the Gi protein-coupled 5-HT1 or the Gq protein-coupled 5-HT2 or the
ionotropic 5-HT3 type receptors similarly increased W and reduced NREM and REM sleep in
the rat [reviewed in (52)].
Most of the 5-HTergic innervation of brain regions involved in S–W regulation
originates from the dorsal raphe nucleus (DRN) (40). The ﬁring rate of DRN neurons
decreases during NREM sleep relative to W and ﬁring virtually ceases during REM sleep
(48).
Based on the above-mentioned ﬁndings, it is reasonable to expect that acute adminis-
tration of SSRIs, prolonging 5-HT effect in 5-HTergic synapses (19), increases W and
decreases NREM and REM sleep. Indeed, the most consistent effect of SSRIs is REM sleep
suppression (73). However, the effect of SSRIs on NREM sleep and W is ambiguous. Acute
administration of some SSRIs caused a biphasic effect. Zimeldine (81) and alaproclate (82)
ﬁrst increased W, but this was followed by an increase in NREM sleep. No such effect was
shown for ﬂuoxetine yet. Thus, for the ﬁrst time, our present results demonstrate the biphasic
effect of ﬂuoxetine in rats. The pattern was similar to that seen after apomorphine, except that
a smaller rebound occurred after the initial inhibition of slow waves and DS (Fig. 3b). The
same applies for delta intensity that was elevated for 5 h with an onset in the third hour
(Fig. 4b).
In contrast to apomorphine, ﬂuoxetine has a slow degradation rate with an elimination
half-life of 5 h (17). The only active metabolite of ﬂuoxetine, norﬂuoxetine has an even
longer elimination half-life of 15 h (17) and elevates 5-HT level in the cortex of rats for as
long as 18 h (61). Therefore, ﬂuoxetine treatment might have increased 5-HT levels for the
whole recording period in our experiments. This may explain the strong suppression of REM
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sleep during the LP followed by only a weak recovery in the DP (Fig. 2). It is more difﬁcult to
ﬁnd an explanation for the fact that NREM sleep recovery was complete by the end of the LP
despite the supposedly high 5-HT level (Fig. 2). Prolonged increase in forebrain extracellular
5-HT levels is known to elicit a negative feedback process involving 5-HT1A-type auto-
receptors in DRN neurons (4) that decreased 5-HT release, but a similar mechanism was not
described in the case of acute SSRI applications. A possible explanation might be the
desensitization of other 5-HT receptor subtypes.
Though chronic SSRI treatment is anxiolytic, acute SSRI application might be anxio-
genic (30). It was also suggested that W-promoting effect of SSRIs might be secondary (81),
as SSRI administration was found to cause behavioral and motor activation (9). Thus, it
seems that increased 5-HT levels exert complex effects on systems underlying S–W
regulation and on other behavioral systems that interact with S–W regulation (80).
Yohimbine. The most important NAergic cell group involved in the S–W regulation is located
in the LC from where axons innervate most of the forebrain (42). NA acts through α1-, α2-,
and β-type receptors, each type containing multiple subtypes (16).
NA is crucial in the maintenance of aroused W. LC neurons ﬁre at moderate frequency
during W while their activity is diminished during NREM sleep and almost non-existent
during REM sleep (5). Many NAergic LC neurons increase their ﬁring activity in response to
novel stimuli and their discharges precede behavioral responses (69). Both kinds of
activations lead to an increased cortical release of NA and the consequent EEG
activation (6).
Drugs that either stimulate the release or block the reuptake of NA increase W (10).
Systemic administration of excitatory α1-adrenoceptor antagonists, like prazosin (58), or
agonists of the inhibitory α2-adrenoceptors, like guanfacine facilitate sleep (66). By contrast,
antagonists of the α2-adrenoceptor, such as yohimbine, delay and suppress sleep (58), most
likely by blocking the α2-type autoreceptors on NAerg neurons and enhancing NA release
(68).
In our experiment, yohimbine induced a long-lasting suppression of delta power
(Fig. 3c) and DS (Fig. 2). It was obvious not only during the LP, but also in the DP. Not
only the total amount of sleep and delta power was below the control value, but delta intensity
during NREM sleep as well, at least during the LP (Fig. 4c). These long-lasting effects are in
accordance with the pharmacokinetics of yohimbine, which is characterized by rapid
distribution followed by a slow elimination with a half-life of 7–8 h (36). The continuous
presence of yohimbine in the brain tissue and the consequent increased NA release might
have been one of the causes why no recovery of DS could occur during the whole recording
time, not even in the DP, though the loss of this sleep stage was the strongest among the
applied drugs. The long-lasting increase in NA level might also account for the strong
suppression and very weak and delayed recovery of REM sleep (Fig. 2).
Although ﬂuoxetine potentially had an even longer effect, the increase in SP and the
putative decrease of synaptic efﬁcacy at 5-HT synapses were sufﬁcient to overcome drug
effect. It is difﬁcult to imagine that similar mechanisms were unable to force out recovery in
the case of yohimbine. An alternate explanation for the effect of yohimbine might be that SP
did not increase signiﬁcantly, as restorative processes may have occurred even if the EEG
was desynchronized and slow waves were blocked. This assumption is also supported by the
decrease of delta intensity during NREM (Fig. 4c). These effects may be mediated through
α2 receptors. Yohimbine equally blocks presynaptic and postsynaptic α2 receptors (29).
Blockade of autoreceptors increases the activity of NAergic neurons and the release of
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cortical NA (68), but postsynaptic α2 receptors are also inhibited leading to disinhibition in
the affected cells. The disinhibition could reduce signal-to-noise ratio in the cortex. It was
suggested that the main function of NAergic LC neurons is to enhance the efﬁciency of signal
processing by increasing the signal-to-noise ratio in the cortex through reducing the
background neuronal activity (“noise”) (6). If noise increases due to disinhibition, then it
might lead to an increase of cortical activity in the absence of relevant stimuli, and
consequently to the decrease of delta activity without inﬂuencing the restorative functions
of sleep.
Eserine. Cholinergic cells involved in the regulation of W and cortical arousal are located in
the BF and in the mesencephalic PPT and LDT (89). Cholinergic projections from the BF
innervate the whole cortical mantle (88), while PPT and LDT project to the brainstem,
hypothalamus, thalamus, and the BF (74). ACh exerts its effect mainly through different
subtypes of muscarinic receptors (mAChRs). In the rat brain, M1–M4 subtypes have been
identiﬁed (46), though nicotinic ACh receptors (nAChRs) are also widely distributed in the
brain (20).
The ﬁring rate of BF ACh neurons is highest during W and REM sleep with a minimal
activity during NREM sleep (33). ACh released from cortical projections of the BF closes
different K+ channels in pyramidal cells via mAChRs (50), thus increasing their excitability
(31) and even causing depolarization and excitation (31). Cortical desynchronization can be
induced by mAChR agonists, mimicking behavioral activation related to emotional reactions,
attention, and learning while mAChR antagonists produce EEG slowing and impaired
cognition (84). Centrally acting selective AChE inhibitors were found to cause increased
W and a decreased NREM and REM sleep (39).
In our experiments, eserine had a moderate suppressing effect on delta power (Fig. 3d)
and DS (Fig. 2) during the deprivation period (hours 1–2). This moderate loss was almost
completely recovered already during the initial period (hours 1–4), during which delta
intensity was also slightly increased (Fig. 4d). Similar to the case of ﬂuoxetine, this biphasic
effect was not reported earlier in the literature, as previous studies focused mostly on the acute
W increase, neglecting the subsequent increase in sleep and delta power. Thus, this study is
the ﬁrst description of such a fast recovery. In addition, eserine seemed to delay the delta
power curve by 1 h. Interestingly, this delay was not seen in REM sleep (data not shown).
The main effect of eserine is the enhancement of ACh transmission at all active
cholinergic synapses, and probably extrasynaptically as well. The majority of these synaptic
effects probably occur via muscarinic receptors, though the role of nicotinic receptors should
also be considered as nicotine and nAChR agonists were found to excite pyramidal neurons in
the prefrontal cortex (86).
Similarly to apomorphine, eserine also has a short (20–30 min) elimination half-life in
the brain tissue (41). This fast elimination can explain its short-lasting sleep suppression
effects.
ACh was implicated in the generation of REM sleep (43) and cholinergic cells are
activated during REM sleep (33). Microinjection of the AChE inhibitor neostigmine into the
dorsal pontine tegmentum evoked REM sleep in rats (59). After systemic administration of
various AChE inhibitors such as eserine (45), increased REM sleep was reported in rats.
However, some studies reported decreased REM sleep after systemic injections (70). It was
suggested that physostigmine effect on REM sleep depends on the actual S–W stage at the
time of the application. Physostigmine can elicit REM sleep when injected during NREM
sleep but when injected during W, it evokes a more aroused state with decreased REM sleep
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(71). The present data support this hypothesis as REM sleep slightly decreased after eserine
administration in the ﬁrst 4 h.
Distinct recovery of sleep stages containing different amount of delta waves
In this study, recovery of sleep stages with different levels of delta activity were also analyzed
after pharmacologically evoked SD. NREM sleep stages with different amount of delta waves
recovered differently after SD. In most cases, loss of the stage with low level of delta activity
(i.e., LS) during the initial period was not recovered later. Yohimbine represented an
exception to this rule as minimal LS loss in the initial period was recovered later, but this
recovery was more related to DS recovery which recovered partly as LS: Moreover, in the
case of apomorphine, LS loss continuously increased during the whole recording period.
These ﬁndings are in agreement with the results of previous studies reaching the conclusion
that LS does not seem to be an important feature of RS (62). This phenomenon supports the
current hypothesis that the subject of the homeostatic regulation may not be the broadly
deﬁned sleep stage but instead the slow delta waves (87). In this conception, delta waves are
markers and/or correlates of several important processes which may occur during only deep
sleep (e.g., memory consolidation, plastic changes, etc.) and these processes may be linked
directly to the function of NREM sleep (76).
REM sleep recovery
REM sleep strongly depends on NREM sleep as in healthy sleep, the presence of some
NREM sleep is a prerequisite for the occurrence of REM sleep. During the sleep-dominated
LP, the NREM–REM cycle has a time period of about 12–20 min in rats (78). In this study, all
drugs reduced REM sleep in the ﬁrst 4 h, though this effect was only moderate after eserine
treatment (Fig. 2). In the case of apomorphine and eserine, full recovery and even a slight
overcompensation was seen by the end of the recording in parallel with changes in DS. This
observation might indicate a priming effect of deep NREM sleep in REM sleep generation.
In contrast to apomorphine and eserine, minimal recovery of REM was seen after
ﬂuoxetine and yohimbine, though lost DS was recovered after ﬂuoxetine treatment. The two
activating systems involved, 5-HTerg and NAerg, are well known to have a minimal activity
in REM sleep suggesting a speciﬁc inhibitory control over REM generation (34). As both
ﬂuoxetine and yohimbine have a long half-life, the lacking recovery of REM sleep was
probably due to the long-lasting increase in the 5-HTerg and NAerg transmission.
Concluding remarks
In this study, suppression of delta activity and increased W were induced pharmacologically
by different drugs related to different arousal systems (DAergic, 5-HTergic, NAergic, and
AChergic systems) and recovery was followed for 18 h. In the case of ﬂuoxetine and eserine,
recovery of NREM sleep was fast and was completed by the end of the LP due to the biphasic
pattern (suppression followed by rebound) ﬁrst demonstrated for these drugs in the present
experiments.
Even more interestingly, apomorphine caused a very strong suppression of delta activity
followed by a very intense recovery of delta power and DS that increased above the control
level at the expense of LS. Though apomorphine is not completely speciﬁc to the DAergic
system, the present results may suggest that the DAergic system is more important in S–W
regulation and NREM sleep homeostasis than previously suggested and further experiments
using more selective drugs for the different DA receptors are justiﬁed.
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In a similar vein, the long-lasting delta power and NREM sleep suppression caused by
yohimbine might be worth further examination. The fact that delta power and sleep loss
increased in the course of the recording might indicate that either the NA system has the
utmost strength among the examined activating systems, or that restorative functions
occurring normally during NREM sleep were not blocked. Even longer follow-up of the
recovery process is needed to ﬁnd out whether NREM sleep recovery eventually occurs. In
addition, selective manipulation of the various NA receptors should be carried out to more
precisely characterize the mechanism by which NA inﬂuences the regulation of cortical
activity and the S–W cycle.
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